

## **100TH GENERAL ASSEMBLY**

## State of Illinois

# 2017 and 2018

#### HB5156

by Rep. Sara Feigenholtz

### SYNOPSIS AS INTRODUCED:

225 ILCS 65/65-35.1 225 ILCS 65/65-40

was 225 ILCS 65/15-20

Amends the Nurse Practice Act. In provisions concerning written collaborative agreements, restores the ability of podiatric physicians to collaborate with advanced practice registered nurses. Makes other changes. Effective immediately.

LRB100 17650 XWW 32821 b

HB5156

1

7

AN ACT concerning regulation.

# Be it enacted by the People of the State of Illinois, represented in the General Assembly:

Section 5. The Nurse Practice Act is amended by changing
Sections 65-35.1 and 65-40 as follows:

6 (225 ILCS 65/65-35.1)

(Section scheduled to be repealed on January 1, 2028)

8 Sec. 65-35.1. Written collaborative agreement; temporary 9 practice. Any advanced practice registered nurse required to into a written collaborative agreement 10 enter with а 11 collaborating physician or collaborating podiatrist is 12 authorized to continue to practice for up to 90 days after the 13 termination of a collaborative agreement provided the advanced 14 practice registered nurse seeks any needed collaboration at a local hospital and refers patients who require services beyond 15 16 the training and experience of the advanced practice registered 17 nurse to a physician or other health care provider.

18 (Source: P.A. 99-173, eff. 7-29-15; 100-513, eff. 1-1-18.)

19 (225 ILCS 65/65-40) (was 225 ILCS 65/15-20)

20 (Section scheduled to be repealed on January 1, 2028)

21 Sec. 65-40. Written collaborative agreement; prescriptive 22 authority. HB5156

(a) A collaborating physician or podiatric physician may, 1 2 but is not required to, delegate prescriptive authority to an 3 advanced practice registered nurse as part of a written collaborative agreement. This authority may, but 4 is not 5 required to, include prescription of, selection of, orders for, administration of, storage of, acceptance of samples of, and 6 dispensing over the counter medications, legend drugs, medical 7 8 gases, and controlled substances categorized as any Schedule 9 III through V controlled substances, as defined in Article II 10 of the Illinois Controlled Substances Act, and other 11 preparations, including, but not limited to, botanical and 12 herbal remedies. The collaborating physician or podiatric 13 physician must have a valid current Illinois controlled 14 substance license and federal registration to delegate 15 authority to prescribe delegated controlled substances.

(b) To prescribe controlled substances under this Section, an advanced practice registered nurse must obtain a mid-level practitioner controlled substance license. Medication orders shall be reviewed periodically by the collaborating physician <u>or podiatric physician</u>.

(c) The collaborating physician <u>or podiatric physician</u> •
shall file with the Department and the Prescription Monitoring
Program notice of delegation of prescriptive authority and
termination of such delegation, in accordance with rules of the
Department. Upon receipt of this notice delegating authority to
prescribe any Schedule III through V controlled substances, the

licensed advanced practice registered nurse shall be eligible to register for a mid-level practitioner controlled substance license under Section 303.05 of the Illinois Controlled Substances Act.

5 (d) In addition to the requirements of subsections (a), 6 (b), and (c) of this Section, a collaborating physician <u>or</u> 7 <u>podiatric physician</u> may, but is not required to, delegate 8 authority to an advanced practice registered nurse to prescribe 9 any Schedule II controlled substances, if all of the following 10 conditions apply:

11 (1) Specific Schedule II controlled substances by oral 12 dosage or topical or transdermal application may be the delegated Schedule 13 delegated, provided that ΙI 14 controlled substances are routinely prescribed by the 15 collaborating physician or podiatric physician. This 16 delegation must identify the specific Schedule ΙI 17 controlled substances by either brand name or generic name. Schedule II controlled substances to be delivered by 18 19 injection or other route of administration may not be 20 delegated.

(2) Any delegation must be controlled substances that
 the collaborating physician <u>or podiatric physician</u>
 prescribes.

(3) Any prescription must be limited to no more than a
 30-day supply, with any continuation authorized only after
 prior approval of the collaborating physician <u>or podiatric</u>

HB5156

HB5156

1

physician.

2 (4) The advanced practice registered nurse must 3 discuss the condition of any patients for whom a controlled 4 substance is prescribed monthly with the delegating 5 physician.

6 (5) The advanced practice registered nurse meets the 7 education requirements of Section 303.05 of the Illinois 8 Controlled Substances Act.

9 (e) Nothing in this Act shall be construed to limit the 10 delegation of tasks or duties by a physician to a licensed 11 practical nurse, a registered professional nurse, or other 12 persons. Nothing in this Act shall be construed to limit the 13 method of delegation that may be authorized by any means, 14 including, but not limited to, oral, written, electronic, 15 standing orders, protocols, guidelines, or verbal orders.

(f) Nothing in this Section shall be construed to apply to any medication authority including Schedule II controlled substances of an advanced practice registered nurse for care provided in a hospital, hospital affiliate, or ambulatory surgical treatment center pursuant to Section 65-45.

21 (g) <u>(</u>Blank<u>).</u>

(h) Nothing in this Section shall be construed to prohibitgeneric substitution.

(i) Nothing in this Section shall be construed to apply to
an advanced practice registered nurse who meets the
requirements of Section 65-43.

HB5156 - 5 - LRB100 17650 XWW 32821 b

1 (Source: P.A. 100-513, eff. 1-1-18.)

2 Section 99. Effective date. This Act takes effect upon
3 becoming law.